Latest News and Press Releases

DEER PARK, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...

DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...

Xellia’s US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with EtonAgreement Significantly Expands Biorphen Commercial Footprint and Provides Access to...

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton...

Biorphen® Expected to Launch by End of NovemberCompany to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton...

DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...

DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices,...

DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...

ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 ET-105 Acquisition Closed & Application Assigned PDUFA Date of March 17, 2020Company to Host Conference Call and Webcast...